Aurinia Pharmaceuticals (AUPH) stock is soaring 5.08% in pre-market trading on Friday following the release of its impressive second-quarter 2025 financial results and raised full-year guidance. The biopharmaceutical company, focused on therapies for autoimmune diseases, reported significant growth in revenue and earnings, surpassing analyst expectations.

According to the earnings report, Aurinia's revenue for Q2 2025 grew 22% year over year to $70.0 million, beating GAAP expectations by nearly $6.2 million. The company's diluted earnings per share (EPS) reached $0.16, a substantial increase from $0.01 in the same quarter last year and slightly above the analyst estimate of $0.15. This remarkable performance was driven by strong sales of LUPKYNIS, Aurinia's main commercial product for lupus nephritis, and effective cost management following a restructuring in late 2024.

Adding to the positive sentiment, Aurinia's management raised its full-year 2025 revenue guidance to $260 million–$270 million, up from the previous range of $250 million–$260 million. The company also increased its net product sales guidance to $250 million–$260 million. This upward revision in guidance signals management's confidence in the ongoing business trends and commercial execution. Additionally, RBC raised its price target on Aurinia Pharmaceuticals to $9 from $8, maintaining an Outperform rating, which further supports the stock's upward movement.